Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07637734 · ClinicalTrials.gov registry record · Phase 3
Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-3)
A Phase 3 study, sponsored by Verrica Pharmaceuticals.
- Not yet
- Registry status
- Phase 3
- Development phase
- 300
- Enrollment target
NCT07637734 is a Phase 3 study that has not yet begun recruiting, run by Verrica Pharmaceuticals. The registered enrollment target is 300 participants.
The verdict
NCT07637734, a Phase 3 study, has not yet begun recruiting, sponsored by Verrica Pharmaceuticals.
- NOT YET RECRUITING
- Registry status
- Phase 3
- Development phase
- 300 participants
- Enrollment target
Study Summary
This is a Phase 3, double-blind, randomized, vehicle-controlled study (Study number VP-CW-302; referred to as COVE-3 \[Cantharidin and Occlusion in Verruca Epithelium\]) to evaluate the efficacy and safety of YCANTH (VP-102/TO-208) treatment in subjects with common warts.
Interventions
- COMBINATION_PRODUCT VP-102 (US) / TO-208 (Japan)
- COMBINATION_PRODUCT Vehicle (US) / Vehicle (Japan)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2026-06 |
| Est. Completion | 2027-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07637734
The ClinicalTrials.gov registry entry for NCT07637734 describes a study currently listed as not yet recruiting, categorized as Phase 3. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Verrica Pharmaceuticals, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which VP-102 (US) / TO-208 (Japan) is the first listed.
NCT07637734 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07637734 about?
NCT07637734 is a clinical study titled "Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-3)". This is a Phase 3, double-blind, randomized, vehicle-controlled study (Study number VP-CW-302; referred to as COVE-3 \[Cantharidin and Occlusion in Verruca Epithelium\]) to evaluate the efficacy and safety of YCANTH (VP-102/TO-208) treatment in subjects with common warts.
What is the current status of trial NCT07637734?
This trial is currently not yet recruiting. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 2026-06. Estimated completion is 2027-10.
What interventions are being tested in trial NCT07637734?
The interventions under investigation include: VP-102 (US) / TO-208 (Japan) (COMBINATION_PRODUCT), Vehicle (US) / Vehicle (Japan) (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT07637734?
This trial is sponsored by Verrica Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.